Olema Pharmaceuticals
OLMA
65 hedge funds and large institutions have $117M invested in Olema Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 8 closing their positions.
1,075% more call options, than puts
Call options by funds: $47K | Put options by funds: $4K
44% more capital invested
Capital invested by funds: $81.2M → $117M (+$35.7M)
0.14% less ownership
Funds ownership: 82.39% → 82.24% (-0.14%)
3% less funds holding
Funds holding: 67 → 65 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$9.72M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.08M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$729K |
| 4 |
Walleye Capital
New York
|
+$616K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$359K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$3.97M |
| 2 |
Millennium Management
New York
|
-$2.7M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.82M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$824K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$781K |
OLMA Hedge Fund Activity: Q1 2023 in Review
65 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q1 2023, worth a combined $117M — up 44% from $81.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OLMA and 6 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 19 added.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $9.72M. The largest seller was Janus Henderson Group, cutting an estimated $3.97M.
- 65 institutional investors held Olema Pharmaceuticals (OLMA) as of Q1 2023, down from 67 in Q4 2022.
- Funds reported $117M of Olema Pharmaceuticals stock for Q1 2023, up 44% quarter-over-quarter.
- 6 funds opened new Olema Pharmaceuticals positions in Q1 2023 and 8 closed out, a net change of -2 holders.
- The largest Olema Pharmaceuticals buyer in Q1 2023 was Paradigm Biocapital Advisors, an estimated $9.72M added.
- The largest Olema Pharmaceuticals seller in Q1 2023 was Janus Henderson Group, an estimated $3.97M sold.
Based on aggregated 13F filings for Q1 2023.